LOCACORTEN VIOFORM 3 %
CLIOQUINOL : 3 % FLUMETHASONE PIVALATE : 0.02 % · DIN 00074462 · ENDO OPERATIONS LTD.
Health Canada status: MARKETED
What is LOCACORTEN VIOFORM?
LOCACORTEN VIOFORM 3 % contains CLIOQUINOL : 3 % FLUMETHASONE PIVALATE : 0.02 %. It is listed in the Health Canada Drug Product Database under DIN 00074462, held by ENDO OPERATIONS LTD., supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 19-Dec-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LOCACORTEN VIOFORM used for?
Corticosteroid-responsive inflammatory skin disorders complicated by bacterial/fungal infections (e.g., seborrheic/atopic/contact dermatitis, intertrigo, pyoderma) and dermatomycosis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00074462 |
|---|---|
| Brand name | LOCACORTEN VIOFORM |
| Generic / active ingredient | CLIOQUINOL : 3 % FLUMETHASONE PIVALATE : 0.02 % |
| Manufacturer | ENDO OPERATIONS LTD. |
| Strength | 3 % |
| Dosage form | CREAM |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D07CB05 FLUMETASONE AND ANTIBIOTICS |
| AHFS class | 84:04.08.92 ; 84:06.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Dec-2025 |
| Original market date | 1968-12-31 00:00:00 |
How is it administered?
Apply to affected areas in a thin layer 2 to 3 times daily. Use under occlusive dressings is not recommended. Discontinue if no improvement within 1 week.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15-30°C. Protect from heat and freezing.
How is it supplied?
Tubes of 30 g and 50 g.
Contraindications
Viral skin infections, tuberculosis of skin, syphilis, rosacea, acne vulgaris, perioral dermatitis; hypersensitivity to ingredients/iodine; ulcerated areas; eye application; children <2 years.
Warnings and precautions
Avoid contact with eyes/conjunctiva. Do not use in external auditory canal if eardrum is perforated. Risk of systemic effects/adrenal suppression if used on large areas or under occlusion.
What can be used instead?
Other Canadian products sharing ATC code D07CB05 FLUMETASONE AND ANTIBIOTICS. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LOCACORTEN VIOFORM | 3 % | OINTMENT | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 00074470 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.